ChromX Health (“ChromX”) recently has announced the completion of ten millions of CNY in pre-Series A funding, Funsun Capital (复星创富) was the largest institutional investor.
ChromX is a high-tech company focused on developing revolutionary and innovative technologies to fully decode the metabolic molecular information in human breath. The company creatively integrates Micro-electromechanical systems (MEMS), Microfluidics and AI technologies, and develops a breath sequencer based on exhalation metabolomics, which can accurately analyze volatile organic compounds (VOCs) in human breath and detect biomarkers in breath omics, thus reveal metabolic changes in organisms and diagnose diseases.
According to ChromX, the company utilized highly integrated MEMS chips to achieve chip-based gas chromatography and instrument miniaturization. With years of precipitation and experience in microfluidics technology and respiratory VOC detection technology, ChromX has become the world's first company that achieved respiratory point-of-care testing (POCT) in part per trillion.
According to Grand View Research, the global breath analyzers market size was valued at USD 2.38 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 16.5% from 2022 to 2030. This growth is driven by the product advancements, initiatives by key companies, and demand for efficient as well as accurate medical detection devices.
The market for breath analyzers is highly intense. In addition to ChromX, many companies are competing in the breath analyzers market, such as Dräger in Germany, Lifeloc Technologies, Intoximeters and AK GlobalTech in the United States, Bedfont Scientific in the United Kingdom, and Ztsense in China.
Dr. Junqi Wang (王俊奇), founder and CEO of ChromX, stated: " as one of the leaders in the field of MEMS micro-gas chromatography, ChromX appreciates the trust and support of new and old shareholders in the company and industry. The company has not only made new breakthroughs and progress in technology, products, applications, and production in the past year, but also made steps in commercial cooperation, establishing solid and profound strategic cooperation with leading enterprises. With the support of new funds and resources, ChromX will continue to break through the industry, continue to lead MEMS micro gas chromatography technology, and promote the application of VOC detection technology.
This round of financing for ChromX was exclusively invested by Funsun Capital (复星创富), with follow-on investments from Guangzhou Science City (广州科学城创投), Jun Tiancheng (上海珺天诚) and Greater Bay Area Collaborative Innovation Research Institute (大湾区协同院).